1. A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Lunning, M.; Bierman, P.; Bociek, R.; Armitage, J.; Heires, P.; Blumel, S.; Hohenstein, M.; Lyden, L.; Vose, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. (12th June 2019) Authors: Witzig, T.E.; Maddocks, K.; de Vos, S.; Lyons, R.; Edenfield, W.; Sharman, J.; Vose, J.; Yimer, H.; Wei, H.; Chan, E.; Patel, P.; Di Simone, C.; Gandhi, M.; Vaughn, J.; Kolibaba, K.; Cheson, B.; Samaniego, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Extreme Flooding and Nitrogen Dynamics of a Blackwater River. Issue 12 (10th December 2021) Authors: Neville, J. A.; Emanuel, R. E.; Nichols, E. G.; Vose, J. Journal: Water resources research Issue: Volume 57:Issue 12(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS. (12th June 2019) Authors: Okosun, J.; Bödör, C.; Batlevi, C.; Nagy, N.; Michot, J.; Schneider, T.; Alizadeh, H.; Simon, Z.; Vose, J.; Younes, A.; Ribrag, V.; Fitzgibbon, J.; Yang, J.; Agarwal, S.; Newberry, K.J.; Michaud, N.R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM. (23rd June 2022) Authors: Wang, Y.; Jain, P.; Locke, F.; Maurer, M.; Frank, M.; Munoz, J.; Dahiya, S.; Beitinjaneh, A.; Jacobs, M.; Mcguirk, J.; Vose, J.; Goy, A.; Andreadis, C.; Hill, B.; Dorritie, K.; Oluwole, O.; Deol, A.; Shah, B.; Paludo, J.; Wang, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL LYMPHOMA: PHASE II RESULTS. (12th June 2019) Authors: Lunning, M.; Horwitz, S.; Advani, R.; Vose, J.; Lee, H.; Mehta‐Shah, N.; Zain, J.; Haverkos, B.; Lechowicz, M.; Moskowitz, A.; Heires, P.; Lyden, L.; Ansell, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 280 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗